Peptide profile
Thymalin/Thymulin
Thymic peptide restoring immune vitality with age · also known as Thymalin, Thymulin, FTS, Facteur Thymique Sérique, Serum Thymic Factor, Thymic Humoral Factor
Compare Thymalin/Thymulin with other peptides →Summary
Thymalin is a thymic peptide preparation derived from calf thymus glands, while Thymulin (FTS) is a naturally occurring nonapeptide produced by thymic epithelial cells that requires zinc as a cofactor for biological activity. Together they represent thymic-origin immunomodulatory compounds that restore and regulate T-lymphocyte differentiation, maturation, and function. They are used primarily to support immune system integrity, combat immunosenescence, and may have applications in anti-aging and recovery protocols.
- Typical dose
- 5–10 mg/day (Thymalin); Thymulin typically dosed at 1–10 mcg/day in research contexts
- Half-life
- ~30 minutes (Thymulin native peptide); Thymalin effects persist longer due to multi-peptide composition
- Route
- Subcutaneous, Intramuscular
- Cycle length
- 10–30 days per cycle, repeated seasonally or as needed
Mechanism
How it works
Thymulin binds to specific receptors on T-lymphocyte precursors in a zinc-dependent manner, promoting their differentiation into mature T-cell subsets (CD4+ and CD8+ cells) and modulating cytokine production including IL-2, IL-4, and interferon-gamma. It acts on the hypothalamic-pituitary-thyroid and neuroendocrine axes, influencing GnRH release and establishing bidirectional communication between the immune and endocrine systems. Thymalin, as a broader thymic extract, contains multiple bioactive peptides including thymulin that collectively upregulate innate and adaptive immunity by restoring thymic output and T-cell receptor signaling fidelity.
Reported in research
Benefits
- Restoration and enhancement of T-lymphocyte maturation and differentiation, supporting adaptive immune function
- Reduction of immunosenescence — counteracting age-related thymic involution and declining T-cell output
- Anti-inflammatory modulation via regulation of pro-inflammatory cytokines (TNF-α, IL-6) without broad immunosuppression
- Potential neuroendocrine support including modulation of the HPA axis, pain perception, and sleep-wake regulation
- Improved recovery from infections, post-surgical states, and chronic illness through immune reconstitution
- Antioxidant and cytoprotective effects observed in animal and limited human studies
Context, not a prescription
Dosing
- Typical range
- 5–10 mg/day (Thymalin); Thymulin typically dosed at 1–10 mcg/day in research contexts (Subcutaneous, Intramuscular)
- Cycle length
- 10–30 days per cycle, repeated seasonally or as needed
- Half-life
- ~30 minutes (Thymulin native peptide); Thymalin effects persist longer due to multi-peptide composition
Safety
Side effects & contraindications
Possible side effects
- Mild injection site reactions (redness, swelling, transient discomfort)
- Transient low-grade fever or flu-like symptoms during immune activation phase
- Possible headache in early days of use
- Rare allergic or hypersensitivity reactions, particularly in those sensitive to bovine-derived products
Contraindications
- Active autoimmune disorders (e.g., lupus, rheumatoid arthritis, MS) — immune stimulation may exacerbate flares
- Organ transplant recipients on immunosuppressive regimens — may counteract anti-rejection therapy
- Known allergy or hypersensitivity to bovine thymic extracts or zinc-containing compounds
- Pregnancy and lactation — insufficient safety data available
Research information, not medical advice. Always consult a licensed clinician before considering any peptide.
In depth
Full profile
What it does
Users often report fewer infections, improved energy levels, faster recovery from illness, and a general sense of vitality — particularly older users whose immune systems have declined with age.
How it works
Think of your thymus like a military academy that trains soldiers (immune cells). As you age, the academy closes down. Thymalin/Thymulin is like reopening that academy and bringing in experienced instructors — your immune 'soldiers' start getting trained again properly.
When injected, these peptides travel to immune tissues and interact with immature immune cells (T-cell precursors), guiding them to mature into functional defenders. They also communicate with your brain and hormonal system, since the immune and endocrine systems are closely linked.
What to expect
Early immune changes can be detected within 1–2 weeks, though subjective improvements in energy and resistance to illness may take 3–4 weeks to notice.
- Week 1: Initial immune activation; some users notice mild injection site reactions or a brief adjustment period with slight fatigue
- Weeks 2-4: Gradual improvement in immune markers; users often report feeling more resilient and energetic, fewer cold symptoms
- Weeks 4-8: More sustained immune balance; improved recovery from illness, potential improvements in general wellbeing and vitality, especially in older users
Good to know
- Start with a lower dose and observe your body's response for the first few days
- Consult with a healthcare provider familiar with peptide therapy before beginning use
Staying safe
- Mild soreness or redness at the injection site
- Occasional tiredness or mild flu-like feeling in the first few days
Avoid if you have:
- People with autoimmune diseases like lupus or multiple sclerosis
- Organ transplant recipients taking anti-rejection medications
- Pregnant or breastfeeding individuals
Mechanism of action
Thymulin (pyro-Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) is a zinc-dependent nonapeptide secreted by thymic epithelial cells. In its zinc-bound form (Zn-FTS), it binds to specific T-lymphocyte membrane receptors, inducing nuclear translocation of transcription factors that promote expression of T-cell differentiation markers including Thy-1, Lyt-1/2, and T-cell receptor components. It modulates cytokine expression profiles by upregulating IL-2 and IFN-γ while downregulating excessive TNF-α and IL-6, favoring a balanced Th1/Th2 response. Thymulin also interfaces with the neuroendocrine axis: hypothalamic thymulin receptors influence GnRH pulsatility, and the peptide modulates opioid-mediated pain pathways via endorphin interaction. Thymalin, as a polypeptide extract, contains thymulin alongside thymopoietin fragments, thymosin fractions, and other thymic humoral factors, providing broader immunoregulatory activity through multiple receptor systems.
Following subcutaneous or intramuscular administration, Thymalin distributes rapidly to lymphoid tissues including thymus remnants, spleen, and lymph nodes. Thymulin's short native half-life (~30 minutes) is compensated by downstream transcriptional effects that persist for days. It upregulates thymic output of naïve T-cells, restores T-cell receptor repertoire diversity (TCR Vβ diversity), and reduces senescent (p16+/p21+) immune cell burden. It also exhibits modulatory effects on the hypothalamic-pituitary-gonadal axis and has been shown to attenuate HPA axis hyperactivation in stress states.
Pharmacodynamics
Peak plasma levels within 15–30 minutes post-injection. Immunological effects (measurable T-cell subset changes) detectable within 5–7 days. Functional immune reconstitution requires 2–4 weeks of sustained dosing.
Quantitative increases in circulating CD3+, CD4+, and CD8+ T-cell subsets; normalization of CD4:CD8 ratio in immunocompromised individuals; improved NK cell cytotoxicity; reduced inflammatory cytokine burden (IL-6, TNF-α); restoration of delayed-type hypersensitivity (DTH) responses; and improved antibody response to vaccination in elderly subjects.
Timeline
- Days 1-3: Peptide distributes to lymphoid tissues; initial thymic epithelial receptor engagement; possible transient cytokine release manifesting as mild fever or fatigue. Serum zinc partitioning to Thymulin-zinc complex may temporarily reduce free zinc levels.
- Weeks 1-2: Measurable increases in circulating CD3+ T-cells and NK cell activity; normalization of IL-2 secretion capacity in T-cells; improved DTH skin test reactivity in anergic individuals; reduction in inflammatory cytokine baseline (IL-6, CRP).
- Weeks 2-8: Sustained improvement in naïve T-cell output and TCR diversity; improved antibody responses to antigenic challenges; potential HPA axis normalization with improved stress resilience; anti-aging effects on immune phenotype including reduction of terminally differentiated effector memory T-cells (TEMRA) in older subjects.
Comparisons
- Thymalin/Thymulin — effectiveness Moderate, safety Good, cost $$, Medium to use
- Thymosin Alpha-1 (Tα1) — effectiveness High, safety Good, cost $$$, Medium to use
- Thymosin Beta-4 (TB-500) — effectiveness High, safety Good, cost $$$, Medium to use
Adverse effects
Common:
- Injection site erythema and transient induration (most common, typically resolves within 24–48 hours)
- Transient pyrexia (low-grade fever <38.5°C) due to cytokine release during immune activation in the first 1–3 days
Rare:
- Type I hypersensitivity reactions (<1% incidence) in individuals with pre-existing bovine protein sensitization
- Paradoxical immune activation worsening in subclinical autoimmune conditions — estimated <2% in reported clinical series
Contraindications & risk mitigation
Contraindicated in:
- Systemic lupus erythematosus (SLE) and other systemic autoimmune conditions — thymic peptide-driven T-cell activation may precipitate flare
- Solid organ transplant recipients receiving calcineurin inhibitors or mTOR inhibitors — immunostimulation may compromise graft tolerance
- Patients with hematological malignancies involving lymphoid lineages — theoretical risk of promoting malignant T-cell expansion
- Pre-screen for autoimmune markers (ANA, anti-dsDNA, RF) before initiating therapy in patients with unexplained inflammatory symptoms
- Ensure adequate zinc status (serum zinc >70 mcg/dL) to optimize Thymulin bioactivity; consider co-supplementation with 15–30 mg/day elemental zinc
- Use lowest effective dose for the shortest necessary cycle length; monitor CBC with differential at baseline and mid-cycle in immunocompromised patients
Qué hace
Users often report fewer infections, improved energy levels, faster recovery from illness, and a general sense of vitality — particularly older users whose immune systems have declined with age.
Cómo funciona
Think of your thymus like a military academy that trains soldiers (immune cells). As you age, the academy closes down. Thymalin/Thymulin is like reopening that academy and bringing in experienced instructors — your immune 'soldiers' start getting trained again properly.
When injected, these peptides travel to immune tissues and interact with immature immune cells (T-cell precursors), guiding them to mature into functional defenders. They also communicate with your brain and hormonal system, since the immune and endocrine systems are closely linked.
Qué esperar
Early immune changes can be detected within 1–2 weeks, though subjective improvements in energy and resistance to illness may take 3–4 weeks to notice.
- Week 1: Initial immune activation; some users notice mild injection site reactions or a brief adjustment period with slight fatigue
- Weeks 2-4: Gradual improvement in immune markers; users often report feeling more resilient and energetic, fewer cold symptoms
- Weeks 4-8: More sustained immune balance; improved recovery from illness, potential improvements in general wellbeing and vitality, especially in older users
Bueno saber
- Start with a lower dose and observe your body's response for the first few days
- Consult with a healthcare provider familiar with peptide therapy before beginning use
Manteniéndose seguro
- Mild soreness or redness at the injection site
- Occasional tiredness or mild flu-like feeling in the first few days
Evitar si tienes:
- People with autoimmune diseases like lupus or multiple sclerosis
- Organ transplant recipients taking anti-rejection medications
- Pregnant or breastfeeding individuals
Mecanismo de acción
Thymulin (pyro-Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) is a zinc-dependent nonapeptide secreted by thymic epithelial cells. In its zinc-bound form (Zn-FTS), it binds to specific T-lymphocyte membrane receptors, inducing nuclear translocation of transcription factors that promote expression of T-cell differentiation markers including Thy-1, Lyt-1/2, and T-cell receptor components. It modulates cytokine expression profiles by upregulating IL-2 and IFN-γ while downregulating excessive TNF-α and IL-6, favoring a balanced Th1/Th2 response. Thymulin also interfaces with the neuroendocrine axis: hypothalamic thymulin receptors influence GnRH pulsatility, and the peptide modulates opioid-mediated pain pathways via endorphin interaction. Thymalin, as a polypeptide extract, contains thymulin alongside thymopoietin fragments, thymosin fractions, and other thymic humoral factors, providing broader immunoregulatory activity through multiple receptor systems.
Following subcutaneous or intramuscular administration, Thymalin distributes rapidly to lymphoid tissues including thymus remnants, spleen, and lymph nodes. Thymulin's short native half-life (~30 minutes) is compensated by downstream transcriptional effects that persist for days. It upregulates thymic output of naïve T-cells, restores T-cell receptor repertoire diversity (TCR Vβ diversity), and reduces senescent (p16+/p21+) immune cell burden. It also exhibits modulatory effects on the hypothalamic-pituitary-gonadal axis and has been shown to attenuate HPA axis hyperactivation in stress states.
Farmacodinamia
Peak plasma levels within 15–30 minutes post-injection. Immunological effects (measurable T-cell subset changes) detectable within 5–7 days. Functional immune reconstitution requires 2–4 weeks of sustained dosing.
Quantitative increases in circulating CD3+, CD4+, and CD8+ T-cell subsets; normalization of CD4:CD8 ratio in immunocompromised individuals; improved NK cell cytotoxicity; reduced inflammatory cytokine burden (IL-6, TNF-α); restoration of delayed-type hypersensitivity (DTH) responses; and improved antibody response to vaccination in elderly subjects.
Cronología
- Days 1-3: Peptide distributes to lymphoid tissues; initial thymic epithelial receptor engagement; possible transient cytokine release manifesting as mild fever or fatigue. Serum zinc partitioning to Thymulin-zinc complex may temporarily reduce free zinc levels.
- Weeks 1-2: Measurable increases in circulating CD3+ T-cells and NK cell activity; normalization of IL-2 secretion capacity in T-cells; improved DTH skin test reactivity in anergic individuals; reduction in inflammatory cytokine baseline (IL-6, CRP).
- Weeks 2-8: Sustained improvement in naïve T-cell output and TCR diversity; improved antibody responses to antigenic challenges; potential HPA axis normalization with improved stress resilience; anti-aging effects on immune phenotype including reduction of terminally differentiated effector memory T-cells (TEMRA) in older subjects.
Comparaciones
- Thymalin/Thymulin — efectividad Moderate, seguridad Good, costo $$, Medium de usar
- Thymosin Alpha-1 (Tα1) — efectividad High, seguridad Good, costo $$$, Medium de usar
- Thymosin Beta-4 (TB-500) — efectividad High, seguridad Good, costo $$$, Medium de usar
Efectos adversos
Comunes:
- Injection site erythema and transient induration (most common, typically resolves within 24–48 hours)
- Transient pyrexia (low-grade fever <38.5°C) due to cytokine release during immune activation in the first 1–3 days
Raros:
- Type I hypersensitivity reactions (<1% incidence) in individuals with pre-existing bovine protein sensitization
- Paradoxical immune activation worsening in subclinical autoimmune conditions — estimated <2% in reported clinical series
Contraindicaciones y mitigación de riesgos
Contraindicado en:
- Systemic lupus erythematosus (SLE) and other systemic autoimmune conditions — thymic peptide-driven T-cell activation may precipitate flare
- Solid organ transplant recipients receiving calcineurin inhibitors or mTOR inhibitors — immunostimulation may compromise graft tolerance
- Patients with hematological malignancies involving lymphoid lineages — theoretical risk of promoting malignant T-cell expansion
- Pre-screen for autoimmune markers (ANA, anti-dsDNA, RF) before initiating therapy in patients with unexplained inflammatory symptoms
- Ensure adequate zinc status (serum zinc >70 mcg/dL) to optimize Thymulin bioactivity; consider co-supplementation with 15–30 mg/day elemental zinc
- Use lowest effective dose for the shortest necessary cycle length; monitor CBC with differential at baseline and mid-cycle in immunocompromised patients
Reference data
Specifications
- Molecular formula
- C33H54N12O15S (Thymulin/FTS nonapeptide)
- Molecular weight
- 858.9 g/mol (Thymulin)
- Half-life
- ~30 minutes (Thymulin native peptide); Thymalin effects persist longer due to multi-peptide composition
- Route
- Subcutaneous, Intramuscular
- Cycle length
- 10–30 days per cycle, repeated seasonally or as needed
- Storage
- Lyophilized powder: store at 2–8°C (refrigerated), protected from light. Reconstituted solution: use within 7–10 days when refrigerated at 4°C. Do not freeze reconstituted product. Keep away from repeated freeze-thaw cycles.
- Legal status
- Research compound in most Western countries (USA, EU, UK); not FDA-approved as a drug. Available as a research peptide. Historically used clinically in Russia and Eastern Europe with approved pharmaceutical-grade preparations.
FAQ
Common questions
How does Thymulin's requirement for zinc affect dosing strategy?
Thymulin circulates in both zinc-bound (active) and zinc-free (inactive) forms. Zinc deficiency, common in elderly and immunocompromised individuals, significantly reduces the biologically active fraction. Studies by Mocchegiani et al. demonstrated that zinc supplementation alone can restore Thymulin activity in zinc-deficient aged subjects, suggesting that Thymulin potency is critically zinc-dependent and co-supplementation with zinc (15–30 mg/day) should be considered part of the protocol.
What is the mechanistic distinction between Thymalin and synthetic Thymulin?
Thymalin is a polypeptide complex extracted from bovine thymic glands containing multiple bioactive fractions beyond Thymulin alone, including thymopoietin and thymosin alpha-1 variants. Synthetic Thymulin (FTS) is a defined nonapeptide with a precise pharmacological profile. Thymalin provides broader, less defined immunomodulation while synthetic Thymulin offers more targeted T-cell differentiation activity. Clinical protocols from the St. Petersburg Institute of Bioregulation (Khavinson et al.) have primarily employed Thymalin in human longevity studies.
What does the clinical evidence from Russian studies show?
Longitudinal clinical work by Khavinson and colleagues at the St. Petersburg Institute of Biogerontology (published in Annals of the NYAS and Gerontology journals) demonstrated that Thymalin administration in elderly patients over 6–8 years was associated with reduced infectious morbidity, stabilized immune parameters, and reduced cardiovascular event rates compared to untreated controls. These studies, while compelling, have methodological limitations by Western regulatory standards (small cohorts, limited blinding) and should be interpreted with appropriate caution.
What is the evidence level?
This compound is classified as Limited human data. Some human data exists but trials are small, short-term, or not yet replicated.
Research
Research & sources
Current evidence for Thymalin/Thymulin is rated as Limited human data. Limited human data is available.
- 1. Peptide bioregulators and age-associated pathologies: clinical experience (2003) — Annals of the New York Academy of Sciences, vol. 1019 — Khavinson VKh et al.
- 2. Thymulin and zinc in aging (2000) — Gerontology, vol. 46(5) — Mocchegiani E, Muzzioli M
- 3. The neuroendocrine network: thymulin at the interface (1992) — Clinical Immunology and Immunopathology — Bach JF, Dardenne M
- 4. Immunological effects of thymic peptides in elderly patients (2006) — Bulletin of Experimental Biology and Medicine — Morozov VG, Khavinson VKh
Explore